Advances in ADT Part II: A Guide for APPs Webcast (2023)
Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessment, the AUA has created Advances in ADT: Part II: A Guide for APPs (2023), an educational offering to further update APPs on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment. This educational initiative is comprised of multiple formats, including a live course and on-demand webcast. This live virtual course, which is the cornerstone of the initiative features a multidisciplinary panel, engaging in a lively discussion.
Independent educational grant support provided by:
- Myovant Sciences LTD
- Pfizer Inc.
At the conclusion of ADT Part II: A Guide for APPs, participants will be able to:
- Recognize the need for a multidisciplinary team to provide care for patients with advanced prostate cancer.
- Classify stages of advanced prostate cancer based on clinical and radiographic modalities.
- Apply treatment strategies for different stages of advanced prostate cancer based on current guidelines.
- Evaluate and manage comorbid conditions for patients with advanced prostate cancer on systemic therapies.
- Describe the role of genetic testing to guide therapies for patients with advanced prostate cancer.
- Assess treatment barriers and access to care to therapies for advanced prostate cancer.
For a full listing of all faculty disclosures, please visit the Advances in ADT: Part II: A Guide for APPs live course page and click on the "Faculty" tab.
Education Council Disclosures
COI Review Work Group Disclosures
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 1.00 hours
Release Date: October, 2023
Expiration Date: October, 2024
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation